blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2694681

EP2694681 - PHARMACOGENETIC TEST FOR ANTI-RESORPTIVE THERAPY-ASSOCIATED OSTEONECROSIS OF THE JAW [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.04.2018
Database last updated on 02.08.2024
FormerThe patent has been granted
Status updated on  05.05.2017
FormerGrant of patent is intended
Status updated on  23.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
The Trustees of Columbia University in the City of New York
116th Street and Broadway
New York, NY 10027 / US
[2014/07]
Inventor(s)01 / ZAVRAS, Athanasios
64 Pine Street
Dover, MA 02030 / US
 [2014/07]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[N/P]
Former [2017/23]Atkinson, Jennifer
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
Former [2014/07]Atkinson, Jennifer
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham
B16 8QQ / GB
Application number, filing date12767258.204.04.2012
[2017/23]
WO2012US32150
Priority number, dateUS201161471532P04.04.2011         Original published format: US 201161471532 P
[2014/07]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2012138745
Date:11.10.2012
Language:EN
[2012/41]
Type: A2 Application without search report 
No.:EP2694681
Date:12.02.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 11.10.2012 takes the place of the publication of the European patent application.
[2014/07]
Type: B1 Patent specification 
No.:EP2694681
Date:07.06.2017
Language:EN
[2017/23]
Search report(s)International search report - published on:US27.12.2012
(Supplementary) European search report - dispatched on:EP20.08.2014
ClassificationIPC:C12Q1/68
[2016/50]
CPC:
A61P19/10 (EP); C12Q1/6883 (EP,US); C12Q2600/156 (EP,US);
C12Q2600/172 (EP,US)
Former IPC [2014/07]C12Q1/68, C07H21/04, G01N33/50
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/07]
TitleGerman:PHARMAKOGENETISCHER TEST FÜR DURCH EINE ANTIRESORPTIONSTHERAPIE VERMITTELTE KNOCHENNEKROSE DES KIEFERS[2014/07]
English:PHARMACOGENETIC TEST FOR ANTI-RESORPTIVE THERAPY-ASSOCIATED OSTEONECROSIS OF THE JAW[2014/07]
French:TEST PHARMACOGÉNÉTIQUE POUR UNE OSTÉONÉCROSE ASSOCIÉE À UNE THÉRAPIE INHIBITRICE DE LA RÉSORPTION OSSEUSE DE LA MÂCHOIRE[2014/07]
Entry into regional phase22.10.2013National basic fee paid 
22.10.2013Search fee paid 
22.10.2013Designation fee(s) paid 
22.10.2013Examination fee paid 
Examination procedure22.10.2013Examination requested  [2014/07]
10.03.2015Amendment by applicant (claims and/or description)
09.06.2015Despatch of a communication from the examining division (Time limit: M04)
09.10.2015Reply to a communication from the examining division
23.10.2015Despatch of a communication from the examining division (Time limit: M04)
18.02.2016Reply to a communication from the examining division
24.11.2016Communication of intention to grant the patent
27.03.2017Fee for grant paid
27.03.2017Fee for publishing/printing paid
27.03.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.06.2015
Opposition(s)08.03.2018No opposition filed within time limit [2018/20]
Fees paidRenewal fee
28.04.2014Renewal fee patent year 03
27.04.2015Renewal fee patent year 04
27.04.2016Renewal fee patent year 05
27.04.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.04.2012
AL07.06.2017
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
[2020/34]
Former [2020/31]HU04.04.2012
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
MK07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2020/27]HU04.04.2012
AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2020/15]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
TR07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/25]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/21]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/11]AT07.06.2017
CZ07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
IT07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/10]AT07.06.2017
CZ07.06.2017
EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2018/09]EE07.06.2017
ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/52]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
NL07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/50]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/49]ES07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
NO07.09.2017
GR08.09.2017
Documents cited:Search[X]WO2010005939  (UNIV FLORIDA [US], et al) [X] 1-5,10-14 * the whole document *;
 [X]  - MARIA E SARASQUETE ET AL, "Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 7, doi:10.1182/BLOOD-2008-04-147884, ISSN 0006-4971, (20081001), pages 2709 - 2712, (20080701), XP002647845 [X] 1-5,10-14 * the whole document *

DOI:   http://dx.doi.org/10.1182/BLOOD-2008-04-147884
 [X]  - KATZ J ET AL, "Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw", INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, COPENHAGEN, DK, vol. 40, no. 6, doi:10.1016/J.IJOM.2011.02.002, ISSN 0901-5027, (20110203), pages 605 - 611, (20110208), XP028212192 [X] 1-5,10-14 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ijom.2011.02.002
 [XP]  - P. NICOLETTI ET AL, "Genomewide Pharmacogenetics of Bisphosphonate-Induced Osteonecrosis of the Jaw: The Role of RBMS3", THE ONCOLOGIST, (20120120), vol. 17, no. 2, doi:10.1634/theoncologist.2011-0202, ISSN 1083-7159, pages 279 - 287, XP055132530 [XP] 1-5,10-14 * see whole doc. esp. Table 2 *

DOI:   http://dx.doi.org/10.1634/theoncologist.2011-0202
International search[Y]WO2010005939  (UNIV FLORIDA [US], et al);
 [Y]  - ZHANG ET AL., "Replication study of candidate genes/loci associated with osteoporosis based on genome-wide screening.", OSTEOPOROS INT., (201005), vol. 21, no. 5, pages 785 - 795, XP019798209
 [Y]  - "Homo sapiens chromosome 3 genomic contig NT_022517.18, GRCh37.p5 Primary Assembly", NCBI, (20090610), Database accession no. NT_022517, XP003030207
 [A]  - HOPWOOD ET AL., "Gene expression profile of the bone microenvironment in human fragility fracture bone", BONE, (2009), vol. 44, pages 87 - 101, XP025799345

DOI:   http://dx.doi.org/10.1016/j.bone.2008.08.120
 [A]  - "Homo sapiens chromosome 3 genomic contig NT_022517.18, GRCh37.p9 Primary Assembly", NCBI, (20090610), Database accession no. NT_022517, XP003030208
Examination   - FRITZ ET AL, "RNA-binding Protein RBMS3 Is Expressed in Activated Hepatic Stellate Cells and Liver Fibrosis and Increases Expression of Transcription Factor Prx1", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, (20070724), vol. 371, no. 3, doi:10.1016/J.JMB.2007.06.006, ISSN 0022-2836, pages 585 - 595, XP022168773

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.06.006
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.